Peanut Allergy clinical trials at UC Health
2 in progress, 1 open to eligible people
open to eligible people ages 1-3
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
at UCLA UCSD UCSF
Sorry, accepting new patients by invitation only
The purpose of this study is to assess AR101's safety and tolerability over an extended dosing period.
at UCLA UCSF